

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

10/549317

Applicant: Kenji SOEJIMA et al.
Title: CONSTRUCT COMPRISING RECOGNITION DOMAIN OF AN ANTIBODY
AGAINST VON WILLEBRAND FACTOR-SPECIFIC CLEAVING ENZYME
Int'l. Appl. No.: PCT/JP2004/003602
Int'l. Filing Date: 3/17/2004
Examiner: Unassigned
Art Unit: Unassigned

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §1.56

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Submitted herewith on Form PTO/SB/08 is a listing of the documents known to Applicants in order to comply with Applicants' duty of disclosure pursuant to 37 CFR §1.56.

The submission of the documents herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

TIMING OF THE DISCLOSURE

The listed documents are being submitted in compliance with 37 CFR §1.97(b), within three (3) months of the filing date of the application.

10/549317

RELEVANCE OF EACH DOCUMENT

The documents being cited in the attached PTO/SB/08 was cited as being relevant during the prosecution of the corresponding international application. A copy of the International Search Report is attached setting forth the portion of these documents considered relevant by the examiner. A copy of the documents cited in the Search Report is not being submitted herewith.

Applicants respectfully request that the listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 CFR §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.

Respectfully submitted,

Date

16 September 2005

By



FOLEY & LARDNER LLP

Customer Number: 22428

Telephone: (202) 672-5404

Facsimile: (202) 672-5399

Stephen A. Bent

Attorney for Applicant

Registration No. 29,768

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

Date Submitted: September 16, 2005

(use as many sheets as necessary)

Complete if Known

Application Number	Unassigned
Filing Date	September 16, 2005
First Named Inventor	Kenji SOEJIMA
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	081356-0247

Sheet 1 of 1

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
	A1		JP 10-500705 A		President and Fellows of Harvard College	1/20/1998		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A2	International Search Report of PCT/IP2004/003602.	
	A3	B. PLAIMAUER et al., "Epitope Mapping of Anti-ADAMTS-13 Antibodies in Patients with Acquired TTP", Blood, 11/16/2003, Vol. 102(II), p. 540a.	
	A4	B. PLAIMAUER et al., "Cloning, expression, and functional characterization of the von Willebrand factor-cleaving protease (ADAMTS13)" Blood, 11/15/2002, Vol. 100(10), pp. 3626-3632.	
	A5	HE. GERRITSEN et al., "Partial amino acid sequence of purified von Willebrand factor-cleaving protease", Blood, 9/15/2001, Vol. 98(6), pp. 1654-1661.	
	A6	CC HUANG et al., "Epitope mapping of factor VIII inhibitor antibodies of Chinese origin.", Br. J. Haematol., June 2001, Vol. 113(4), pp. 915-924.	
	A7	MA NARDI et al., "GPIIb- (49-66) is a major pathaophysiologically relevant antigenic determinant for anti-platelet GPIIb of HIV-1-related immunologic thrombocytopenia.", Proc. Natl. Acad. Sci. USA, July 8, 1997, Vol. 94(14), pp. 7589-7594.	
	A8	K. KOKAME et al., "Mutations and common polymorphisms in ADAMTS13 gene responsible for von Willebrand factor-cleaving protease activity", Proc. Natl. Acad. Sci. USA, September 3, 2002, Vol. 99(18), pp. 11902-11907.	
	A9	S. CAL et al., "Cloning, expression analysis, and structural characterization of seven novel human ADAMs, a family of metalloproteinases with disintegrin and thrombospondin-1 domains.", Gene, January 23, 2002, Vol. 283 (1-2), pp. 49-62.	

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.